ProCE Banner Activity

Venetoclax + Rituximab in Relapsed/Refractory CLL

Slideset Download
Conference Coverage
Preliminary data show promising activity for the combination of venetoclax and rituximab, including an ORR of 86% and durable responses in the 55% of patients who achieved MRD negativity.

Released: December 16, 2015

Expiration: December 14, 2016

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Amgen, Inc.

Celgene

Incyte

Merck & Co., Inc.

Millennium Takeda

Seagen